Cue Biopharma, Inc.
Cue Biopharma, Inc. (CUE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cue · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cue Biopharma, Inc. (CUE) measures how much investors pay for each dollar of the company's trailing earnings. CUE's current PE ratio of N/A is calculated by dividing its stock price of $29.28 by its TTM earnings per share of -$4.06.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cue Biopharma, Inc.You CUE | $77M | N/A | — | -$4.06 |
 Barinthus Biotherapeutics plc BRNS | $28M | N/A | — | -$1.64 |
 Coeptis Therapeutics, Inc. COEP | $58M | N/A | — | -$2.81 |
 Equillium, Inc. EQ | $102M | N/A | — | -$0.24 |
 IO Biotech, Inc. IOBT | $1M | N/A | — | -$1.45 |
 Century Therapeutics, Inc. IPSC | $188M | N/A | — | -$0.11 |
 Medicus Pharma Ltd. Common Stock MDCX | $7M | N/A | — | -$1.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-8.42 | — | |
2024-12-31 FY2024 | — | $-21.66 | — | |
2023-12-31 FY2023 | — | $-33.26 | — | |
2022-12-31 FY2022 | — | $-44.61 | — | |
2021-12-31 FY2021 | — | $-42.35 | — | |
2020-12-31 FY2020 | — | $-46.83 | — | |
2019-12-31 FY2019 | — | $-49.95 | — | |
2018-12-31 FY2018 | — | $-58.08 | — | |
2017-12-31 FY2017 | — | $-33.77 | — | |
2016-12-31 FY2016 | — | $-11.13 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cue Biopharma, Inc. (CUE) measures how much investors pay for each dollar of the company's trailing earnings. CUE's current PE ratio of N/A is calculated by dividing its stock price of $29.28 by its TTM earnings per share of -$4.06.
Frequently asked questions
CUE pe ratio · 6 questionsCUE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $29.28 and TTM EPS of -$4.06. Data sourced from Financial Modeling Prep via CUE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cue Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09